液体生検の世界市場2021年-2028年:製品・サービス別(キット・試薬、プラットフォーム・機器、サービス)、循環バイオマーカー別、がん種類別、エンドユーザー別

◆英語タイトル:Liquid Biopsy Market by Product & Service (Kits & Reagents, Platforms & Instruments, and Services), Circulating Biomarker (Circulating Tumor Cells, Extracellular Vesicles, Circulating Tumor DNA [ctDNA], and Other Biomarkers), Cancer Type (Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer, and Other Cancers), and End User (Hospitals & Laboratories and Government & Academic Research Centers): Global Opportunity Analysis and Industry Forecast, 2021–2028
◆商品コード:AMR21JU077
◆発行会社(リサーチ会社):Allied Market Research
◆発行日:2021年5月31日
◆ページ数:235
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single UserUSD6,078 ⇒換算¥668,580見積依頼/購入/質問フォーム
5 UserUSD6,821 ⇒換算¥750,310見積依頼/購入/質問フォーム
Enterprise UserUSD9,512 ⇒換算¥1,046,320見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はAllied Market Research社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Allied Market Research社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

本調査資料では、液体生検の世界市場について調査し、イントロダクション、エグゼクティブサマリー、市場概要、製品・サービス別(キット・試薬、プラットフォーム・機器、サービス)分析、循環バイオマーカー別(循環腫瘍細胞、循環腫瘍DNA、細胞外小胞、その他バイオマーカー)分析、がん種類別(肺がん、乳がん、結腸直腸がん、前立腺がん、肝臓がん)分析、エンドユーザー別(病院・研究所、政府・学術研究センター)分析、地域別分析、企業情報などを掲載しています。
・イントロダクション
・エグゼクティブサマリー
・市場概要
・液体生検の世界市場規模:製品・サービス別(キット・試薬、プラットフォーム・機器、サービス)
・液体生検の世界市場規模:循環バイオマーカー別(循環腫瘍細胞、循環腫瘍DNA、細胞外小胞、その他バイオマーカー)
・液体生検の世界市場規模:がん種類別(肺がん、乳がん、結腸直腸がん、前立腺がん、肝臓がん)
・液体生検の世界市場規模:エンドユーザー別(病院・研究所、政府・学術研究センター)
・液体生検の世界市場規模:地域別
・企業情報
【レポートの概要】

The global liquid biopsy market accounted for $1,204.20 million in 2020, and is estimated to reach at $6,804.90 million by 2028, registering a CAGR of 20.9% from 2021 to 2028. Liquid biopsies are non-invasive blood tests that detect tumor DNA & RNA fragments and circulating tumor cells (CTCs), which are released into the blood from the primary tumors and metastatic sites. This results in liquid biopsy to be potentially less expensive as compared to surgical biopsies.

Liquid biopsy is a simple and precise alternative to surgical biopsies, which allows physicians & surgeons to detect & treat cancer at an early stage and acquire tumor information through blood samples. Liquid biopsy also enables the detection of cancer recurrence at earlier than traditional diagnosis methods. Early diagnosis enabled by liquid biopsy tests help healthcare professionals to improve various cancer treatments.
Currently, there are several liquid biopsies in development for oncology. These technological applications and services are being developed for various purposes from research to screening & early detection, assessing biomarker, and providing insights on prognosis & treatment selection. Moreover, some of these tests focus on specific cancer and others are being developed as screening tool for multiple solid tumor cancers.

Rise in incidences and prevalence of various cancer types, advantages of liquid biopsy technology, surge in demand of non-invasive procedures, and favorable government initiatives supplement the market growth. However, lack of awareness about cancer and its risk factors, along with limited access to advanced cancer diagnostics technologies in developing regions are expected to hinder the market growth. Furthermore, advantages of liquid biopsy over traditional invasive diagnostics methods is expected to present lucrative growth opportunities for the market.

The liquid biopsy market is categorized on the basis of product & service, cancer type, circulating biomarker, end user, and region. By product & service, it is divided into kits & reagents, platforms & instruments, and services. By cancer type, it is classified into lung cancer, breast cancer, colorectal cancer, prostate cancer, liver cancer, and other cancers. By circulating biomarker, it is categorized into circulating tumor cell, extracellular vesicle, circulating tumor DNA [ctDNA], and other biomarkers. By end user, it is classified into hospital & laboratory and government & research centers. By region, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Prominent players operating in the global liquid biopsy market include Bio-Rad Laboratories, Inc, Biocept Inc., Guardant Health Inc., Illumina, Inc., F. Hoffmann-La Roche Ltd., Johnson & Johnson, Laboratory Corporation of America Holdings, MDxHealth SA, QIAGEN N.V., and Thermo Fisher Scientific Inc. Product development is the key strategy adopted by the market players to establish their foothold in the market.

KEY BENEFITS FOR STAKEHOLDERS
• The study provides an in-depth analysis of the global liquid biopsy market with current trends and future estimations from 2021 to 2028 to elucidate the imminent investment pockets.
• Comprehensive analysis of factors that drive and restrict the market growth is provided.
• Identification of factors instrumental in changing the market scenario, rise in opportunities, and identification of key companies that can influence this market on a global & regional scale are provided.
• Key players are profiled, and their strategies are analyzed thoroughly to understand the competitive outlook of the market.

Key Market Segments
BY PRODUCT & SERVICE
• Kits & Reagents
• Platforms & Instruments
• Services

BY CIRCULATING BIOMARKER
• Circulating Tumor Cells
• Extracellular Vesicles
• Circulating Tumor DNA [ctDNA]
• Other Biomarkers

BY CANCER TYPE
• Lung Cancer
• Breast Cancer
• Colorectal Cancer
• Prostate Cancer
• Liver Cancer
• Other Cancers  

BY REGION
o North America
 U.S.
 Canada
 Mexico
o Europe
 UK
 Germany
 France
 Italy
 Spain
 Rest of Europe
o Asia-Pacific
 China
 Japan
 India
 Australia
 South Korea
 Taiwan
 Rest of Asia-Pacific
o LAMEA
• Brazil
• Turkey
• Saudi Arabia
• South Africa
• Rest of LAMEA

List of key players profiled in the report
• Bio-Rad Laboratories, Inc
• Biocept Inc.
• Guardant Health Inc.
• Illumina, Inc.
• F. Hoffmann-La Roche Ltd.
• Johnson & Johnson
• Laboratory Corporation of America Holdings
• MDxHealth SA
• QIAGEN N.V
• Thermo Fisher Scientific Inc.

List of the other key players (not included in the report) includes ArcherDX, Inc., CellMax Life, Epigenomics AG, GRAIL Inc., Freenome Holdings Inc, and others.

【レポートの目次】

CHAPTER 1:INTRODUCTION

1.1.Report description
1.2.Key benefits for stakeholders
1.3.Key market segments
1.4.Research methodology

1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

2.1.Key findings of the study
2.2.CXO perspective

CHAPTER 3:MARKET OVERVIEW

3.1.Market definition and scope
3.2.Key findings

3.2.1.Top investment pockets
3.2.2.Top winning strategies
3.2.3.Bargaining power of buyers
3.2.4.Bargaining power of suppliers
3.2.5.Thereat of new entrants
3.2.6.Threat of substitutes
3.2.7.Intensity of competitive rivalry

3.3.Top player positioning, 2020

3.1.Regulation
3.2.Market dynamics

3.2.1.Drivers

3.2.1.1.Rise in incidences and prevalence of various cancer types
3.2.1.2.Increase in demand for safe and non-invasive procedures
3.2.1.3.Advantages of liquid biopsy launches and technology

3.2.2.Restraints

3.2.2.1.Lack of awareness in developing and underdeveloped regions

3.2.3.Opportunities

3.2.3.1.Use of liquid biopsy for treatment of rare cancer
3.2.3.2.Untapped potential of emerging markets

3.3.Impact Analysis
3.4.Impact Analysis of the Covid-19 on Liquid Biopsy Market

CHAPTER 4:LIQUID BIOPSY MARKET, BY PRODUCT & SERVICES

4.1.Overview

4.1.1.Market size and forecast

4.2.Kits & Reagents

4.2.1.Key market trends and opportunities
4.2.2.Market size and forecast, by region
4.2.3.Market share analysis, by country

4.3.Platforms & Instruments

4.3.1.Key market trends and opportunities
4.3.2.Market size and forecast, by region
4.3.3.Market share analysis, by country

4.4.Services

4.4.1.Key market trends and opportunities
4.4.2.Market size and forecast
4.4.3.Market share analysis, by country

CHAPTER 5:LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER

5.1.Overview

5.1.1.Market size and forecast

5.2.Circulating Tumor Cell

5.2.1.Market size and forecast, by region
5.2.2.Market analysis, by country

5.3.Circulating Tumor DNA

5.3.1.Market size and forecast, by region
5.3.2.Market analysis, by country

5.4.Extracellular Vesicles

5.4.1.Market size and forecast, by region
5.4.2.Market analysis, by country

5.5.Other Biomarkers

5.5.1.Market size and forecast, by region
5.5.2.Market analysis, by country

CHAPTER 6:LIQUID BIOPSY MARKET, BY CANCER TYPE

6.1.Overview

6.1.1.Market size and forecast

6.2.Lung Cancer

6.2.1.Market size and forecast, by region
6.2.2.Market analysis, by country

6.3.Breast Cancer

6.3.1.Market size and forecast, by region
6.3.2.Market analysis, by country

6.5.Colorectal Cancer

6.5.1.Market size and forecast, by region
6.5.2.Market analysis, by country

6.6.Prostate cancer

6.6.1.Market size and forecast, by region
6.6.2.Market analysis, by country

6.7.Liver cancer

6.7.1.Market size and forecast, by region
6.7.2.Market analysis, by country

6.8.Other Cancers

6.8.1.Market size and forecast, by region
6.8.2.Market analysis, by country

CHAPTER 7:LIQUID BIOPSY MARKET, BY END USER

7.1.Overview

7.1.1.Market size and forecast

7.2.Hospital and Laboratory

7.2.1.Market size and forecast, by region
7.2.2.Market analysis, by country

7.3.Government and Academic Research Centers

7.3.1.Market size and forecast, by region
7.3.2.Market analysis, by country

CHAPTER 8:LIQUID BIOPSY MARKET, BY REGION

8.1.Overview

8.1.1.Market size and forecast

8.2.North America

8.2.1.Key market trends, growth factors, and opportunities
8.2.2.North America Liquid Biopsy Market, by Product & Service
8.2.3.North America Liquid Biopsy Market, by Circulating Biomarker
8.2.4.North America Liquid Biopsy Market, by Cancer Type
8.2.5.North America Liquid Biopsy Market, by End User
8.2.6.Market size and forecast, by country
8.2.7.U.S.

8.2.7.1.U.S. Liquid biopsy market, by Product & Service
8.2.7.2.U.S. Liquid biopsy market, by Circulating Biomarker
8.2.7.3.U.S. Liquid biopsy market, by Cancer Type
8.2.7.4.U.S. Liquid biopsy market, by End User

8.2.8.Canada

8.2.8.1.Canada Liquid biopsy market, by Product & Service
8.2.8.2.Canada Liquid biopsy market, by Circulating Biomarker
8.2.8.3.Canada Liquid biopsy market, by Cancer Type
8.2.8.4.Canada Liquid biopsy market, by End User

8.2.9.Mexico

8.2.9.1.Mexico Liquid biopsy market, by Product & Service
8.2.9.2.Mexico liquid biopsy market, by Circulating Biomarker
8.2.9.3.Mexico Liquid biopsy market, by Cancer Type
8.2.9.4.Mexico Liquid biopsy market, by End User

8.3.Europe

8.3.1.Key market trends, growth factors, and opportunities
8.3.3.Europe Market size and forecast, by Product & Service
8.3.4.Europe Market size and forecast, by Circulating Biomarker
8.3.5.Europe Market size and forecast, by Cancer Type
8.3.6.Europe Market size and forecast, by End User
8.3.7.Market size and forecast, by country
8.3.8.Germany

8.3.8.1.Germany Liquid biopsy market, by Product & Service
8.3.8.2.Germany Liquid Biopsy Market, by Circulating Biomarker
8.3.8.3.Germany Liquid Biopsy Market, by Cancer Type
8.3.8.4.Germany Liquid Biopsy Market, by End User

8.3.9.France

8.3.9.1.France Liquid biopsy market, by Product & Service
8.3.9.2.France Liquid Biopsy Market, by Circulating Biomarker
8.3.9.3.France Liquid Biopsy Market, by Cancer Type
8.3.9.4.France Liquid Biopsy Market, by End User

8.3.10.UK

8.3.10.1.UK Liquid biopsy market, by Product & Service
8.3.10.2.UK Liquid Biopsy Market, by Circulating Biomarker
8.3.10.3.UK Liquid Biopsy Market, by Cancer Type
8.3.10.4.UK Liquid Biopsy Market, by End User

8.3.11.Italy

8.3.11.1.Italy Liquid biopsy market, by Product & Service
8.3.11.2.Italy Liquid Biopsy Market, by Circulating Biomarker
8.3.11.3.Italy Liquid Biopsy Market, by Cancer Type
8.3.11.4.Italy Liquid Biopsy Market, by End User

8.3.12.Spain

8.3.12.1.Spain Liquid biopsy market, by Product & Service
8.3.12.2.Spain Liquid Biopsy Market, by Circulating Biomarker
8.3.12.3.Spain Liquid Biopsy Market, by Cancer Type
8.3.12.4.Spain Liquid Biopsy Market, by End User

8.3.13.Rest of Europe

8.3.13.1.Rest of Europe Liquid biopsy market, by Product & Service
8.3.13.2.Rest of Europe Liquid Biopsy Market, by Circulating Biomarker
8.3.13.3.Rest of Europe Liquid Biopsy Market, by Cancer Type
8.3.13.4.Rest of Europe Liquid Biopsy Market, by End User

8.4.Asia-Pacific

8.4.1.Key market trends and opportunities
8.4.2.Asia-Pacific Market size and forecast, by Product & Service
8.4.3.Asia-Pacific Market size and forecast, by Circulating Biomarker
8.4.4.Asia-Pacific Market size and forecast, by Cancer Type
8.4.5.Asia-Pacific Market size and forecast, by End User
8.4.6.Market size and forecast, by country
8.4.7.Japan

8.4.7.1.Japan Liquid Biopsy Market, by Product & Service
8.4.7.2.Japan Liquid Biopsy Market, by Circulating Biomarker
8.4.7.3.Japan Liquid Biopsy Market, by Cancer Type
8.4.7.4.Japan Liquid Biopsy Market, by End User

8.4.8.China

8.4.8.1.China Liquid Biopsy Market, by Product & Service
8.4.8.2.China Liquid Biopsy Market, by Circulating Biomarker
8.4.8.3.China Liquid Biopsy Market, by Cancer Type
8.4.8.4.China Liquid Biopsy Market, by End User

8.4.9.Australia

8.4.9.1.Australia Liquid Biopsy Market, by Product & Service
8.4.9.2.Australia Liquid Biopsy Market, by Circulating Biomarker
8.4.9.3.Australia Liquid Biopsy Market, by Cancer Type
8.4.9.4.Australia Liquid Biopsy Market, by End User

8.4.10.India

8.4.10.1.India Liquid Biopsy Market, by Product & Service
8.4.10.2.India Liquid Biopsy Market, by Circulating Biomarker
8.4.10.3.India Liquid Biopsy Market, by Cancer Type
8.4.10.4.India Liquid Biopsy Market, by End User

8.4.11.South Korea

8.4.11.1.South Korea Liquid Biopsy Market, by Product & Service
8.4.11.2.South Korea Liquid Biopsy Market, by Circulating Biomarker
8.4.11.3.South Korea Liquid Biopsy Market, by Cancer Type
8.4.11.4.South Korea Liquid Biopsy Market, by End User

8.4.12.Taiwan

8.4.12.1.Taiwan Liquid Biopsy Market, by Product & Service
8.4.12.2.Taiwan Liquid Biopsy Market, by Circulating Biomarker
8.4.12.3.Taiwan Liquid Biopsy Market, by Cancer Type
8.4.12.4.Taiwan Liquid Biopsy Market, by End User

8.4.13.Rest of Asia-Pacific

8.4.13.1.Rest of Asia-Pacific Liquid Biopsy Market, by Product & Service
8.4.13.2.Rest of Asia-Pacific Liquid Biopsy Market, by Circulating Biomarker
8.4.13.3.Rest of Asia-Pacific Liquid Biopsy Market, by Cancer Type
8.4.13.4.Rest of Asia-Pacific Liquid Biopsy Market, by End User

8.5.LAMEA

8.5.1.Key market trends, growth factors, and opportunities
8.5.3.LAMEA Market size and forecast, by Product & Service
8.5.4.LAMEA Market size and forecast, by Circulating Biomarker
8.5.5.LAMEA Market size and forecast, by Cancer Type
8.5.6.LAMEA Market size and forecast, by End User
8.5.7.Market size and forecast, by country
8.5.8.Brazil

8.5.8.1.Brazil Liquid Biopsy Market, by Product & Service
8.5.8.2.Brazil Liquid Biopsy Market, by Circulating Biomarker
8.5.8.3.Brazil Liquid Biopsy Market, by Cancer Type
8.5.8.4.Brazil Liquid Biopsy Market, by End User

8.5.9.Turkey

8.5.9.1.Turkey Liquid Biopsy Market, by Product & Service
8.5.9.2.Turkey Liquid Biopsy Market, by Circulating Biomarker
8.5.9.3.Turkey Liquid Biopsy Market, by Cancer Type
8.5.9.4.Turkey Liquid Biopsy Market, by End User

8.5.10.Saudi Arabia

8.5.10.1.Saudi Arabia Liquid Biopsy Market, by Product & Service
8.5.10.2.Saudi Arabia Liquid Biopsy Market, by Circulating Biomarker
8.5.10.3.Saudi Arabia Liquid Biopsy Market, by Cancer Type
8.5.10.4.Saudi Arabia Liquid Biopsy Market, by End User

8.5.11.South Africa

8.5.11.1.South Africa Liquid Biopsy Market, by Product & Service
8.5.11.2.South Africa Liquid Biopsy Market, by Circulating Biomarker
8.5.11.3.South Africa Liquid Biopsy Market, by Cancer Type
8.5.11.4.South Africa Liquid Biopsy Market, by End User

8.5.12.Rest of LAMEA

8.5.12.1.Rest of LAMEA Liquid Biopsy Market, by Product & Service
8.5.12.2.Rest of LAMEA Liquid Biopsy Market, by Circulating Biomarker
8.5.12.3.Rest of LAMEA Liquid Biopsy Market, by Cancer Type
8.5.12.4.Rest of LAMEA Liquid Biopsy Market, by End User

CHAPTER 9:COMPANY PROFILES

9.1.BIO-RAD LABORATORIES, INC.

9.1.1.1.Company overview
9.1.1.2.Company snapshot
9.1.1.3.Operating business segments
9.1.1.4.Product portfolio
9.1.1.5.Business performance
9.1.1.6.Key strategic moves and developments

9.2.BIOCEPT, INC.

9.2.1.1.Company overview
9.2.1.2.Company snapshot
9.2.1.3.Operating business segments
9.2.1.4.Product portfolio
9.2.1.5.Business performance
9.2.1.6.Key strategic moves and developments

9.3.GUARDANT HEALTH INC.

9.3.1.1.Company overview
9.3.1.2.Company snapshot
9.3.1.3.Operating business segments
9.3.1.4.Product portfolio
9.3.1.5.Business performance
9.3.1.6.Key strategic moves and developments

9.4.ILLUMINA, INC.

9.4.1.1.Company overview
9.4.1.2.Company snapshot
9.4.1.3.Operating business segments
9.4.1.4.Product portfolio
9.4.1.5.Business performance
9.4.1.6.Key strategic moves and developments

9.5.F. HOFFMANN-LA ROCHE LTD. (FOUNDATION MEDICINE, INC.)

9.5.1.1.Company overview
9.5.1.2.Company snapshot
9.5.1.3.Operating business segments
9.5.1.4.Product portfolio
9.5.1.5.Business performance
9.5.1.6.Key strategic moves and developments

9.6.JOHNSON & JOHNSON

9.6.1.1.Company overview
9.6.1.2.Company snapshot
9.6.1.3.Operating business segments
9.6.1.4.Product portfolio
9.6.1.5.Business performance

9.7.LABORATORY CORPORATION OF AMERICA HOLDINGS

9.7.1.1.Company overview
9.7.1.2.Company snapshot
9.7.1.3.Operating business segments
9.7.1.4.Product portfolio
9.7.1.5.Business performance
9.7.1.6.Key strategic moves and developments

9.8.MDXHEALTH SA

9.8.1.1.Company overview
9.8.1.2.Company snapshot
9.8.1.3.Operating business segments
9.8.1.4.Product portfolio
9.8.1.5.Business performance
9.8.1.6.Key strategic moves and developments

9.9.QIAGEN N.V.

9.9.1.1.Company overview
9.9.1.2.Company snapshot
9.9.1.3.Operating business segments
9.9.1.4.Product portfolio
9.9.1.5.Business performance
9.9.1.6.Key strategic moves and developments

9.10.THERMO FISHER SCIENTIFIC

9.10.1.1.Company overview
9.10.1.2.Company snapshot
9.10.1.3.Operating business segments
9.10.1.4.Product portfolio
9.10.1.5.Business performance
9.10.1.6.Key strategic moves and developments

LIST OF TABLES

TABLE 01.GLOBAL LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2020-2028 ($MILLION)
TABLE 02.LIQUID BIOPSY MARKET FOR KITS & REAGENTS, BY REGION, 2020-2028 ($MILLION)
TABLE 03.LIQUID BIOPSY MARKET FOR PLATFORMS & INSTRUMENTS, BY REGION, 2020-2028 ($MILLION)
TABLE 04.LIQUID BIOPSY MARKET FOR SERVICES, BY REGION, 2020-2028 ($MILLION)
TABLE 05.LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2020–2028 ($MILLION)
TABLE 06.LIQUID BIOPSY MARKET FOR CIRCULATING TUMOR CELL, BY REGION, 2020–2028 ($MILLION)
TABLE 07.LIQUID BIOPSY MARKET FOR CIRCULATING TUMOR DNA, BY REGION, 2020–2028 ($MILLION)
TABLE 08.LIQUID BIOPSY MARKET FOR EXTRACELLULAR VESICLES, BY REGION, 2020–2028 ($MILLION)
TABLE 09.LIQUID BIOPSY MARKET FOR OTHERS, FOR OTHER BIOMARKERS, BY REGION, 2020–2028 ($MILLION)
TABLE 10.LIQUID BIOPSY MARKET, BY CANCER TYPE, 2020–2028 ($MILLION)
TABLE 11.LIQUID BIOPSY MARKET FOR LUNG CANCER, BY REGION, 2020–2028 ($MILLION)
TABLE 12.LIQUID BIOPSY MARKET FOR BREAST CANCER, BY REGION, 2020–2028 ($MILLION)
TABLE 13.LIQUID BIOPSY MARKET FOR COLORECTAL CANCER, BY REGION, 2020–2028 ($MILLION)
TABLE 14.LIQUID BIOPSY MARKET FOR PROSTATE CANCER, BY REGION, 2020–2028 ($MILLION)
TABLE 15.LIQUID BIOPSY MARKET FOR LIVER CANCER, BY REGION, 2020–2028 ($MILLION)
TABLE 16.LIQUID BIOPSY MARKET FOR OTHER CANCER, BY REGION, 2020–2028 ($MILLION)
TABLE 17.LIQUID BIOPSY MARKET, BY END USER, 2020–2028 ($MILLION)
TABLE 18.LIQUID BIOPSY MARKET FOR HOSPITAL AND LABORATORY, BY REGION, 2020–2028 ($MILLION)
TABLE 19.LIQUID BIOPSY MARKET FOR GOVERNMENT AND ACADEMIC RESEARCH CENTER, BY REGION, 2020–2028 ($MILLION)
TABLE 20.LIQUID BIOPSY MARKET REVENUE, BY REGION, 2020–2028 ($MILLION)
TABLE 21.NORTH AMERICA LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2020–2028 ($MILLION)
TABLE 22.NORTH AMERICA LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2020–2028 ($MILLION)
TABLE 23.NORTH AMERICA LIQUID BIOPSY MARKET, BY CANCER TYPE, 2020–2028 ($MILLION)
TABLE 24.NORTH AMERICA LIQUID BIOPSY MARKET, BY END USER, 2020–2028 ($MILLION)
TABLE 25.NORTH AMERICA LIQUID BIOPSY MARKET, BY COUNTRY, 2020–2028 ($MILLION)
TABLE 26.U.S. LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2020–2028 ($MILLION)
TABLE 27.U.S. LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2020–2028 ($MILLION)
TABLE 28.U.S. LIQUID BIOPSY MARKET, BY CANCER TYPE , 2020–2028 ($MILLION)
TABLE 29.U.S. LIQUID BIOPSY MARKET, BY END USER , 2020–2028 ($MILLION)
TABLE 30.CANADA LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2020–2028 ($MILLION)
TABLE 31.CANADA LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2020–2028 ($MILLION)
TABLE 32.CANADA LIQUID BIOPSY MARKET, BY CANCER TYPE, 2020–2028 ($MILLION)
TABLE 33.CANADA LIQUID BIOPSY MARKET, BY END USER, 2020–2028 ($MILLION)
TABLE 34.MEXICO LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2020–2028 ($MILLION)
TABLE 35.MEXICO LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2020–2028 ($MILLION)
TABLE 36.MEXICO. LIQUID BIOPSY MARKET, BY CANCER TYPE, 2020–2028 ($MILLION)
TABLE 37.MEXICO. LIQUID BIOPSY MARKET, BY END USER, 2020–2028 ($MILLION)
TABLE 38.EUROPE LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2020–2028 ($MILLION)
TABLE 39.EUROPE LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2020–2028 ($MILLION)
TABLE 40.EUROPE LIQUID BIOPSY MARKET, BY CANCER TYPE, 2020–2028 ($MILLION)
TABLE 41.EUROPE LIQUID BIOPSY MARKET, BY END USER, 2020–2028 ($MILLION)
TABLE 42.EUROPE LIQUID BIOPSY MARKET, BY COUNTRY, 2020–2028 ($MILLION)
TABLE 43.GERMANY LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2020–2028 ($MILLION)
TABLE 44.GERMANY LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2020–2028 ($MILLION)
TABLE 45.GERMANY LIQUID BIOPSY MARKET, BY CANCER TYPE, 2020–2028 ($MILLION)
TABLE 46.GERMANY LIQUID BIOPSY MARKET, BY END USER, 2020–2028 ($MILLION)
TABLE 47.FRANCE LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2020–2028 ($MILLION)
TABLE 48.FRANCE LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2020–2028 ($MILLION)
TABLE 49.FRANCE LIQUID BIOPSY MARKET, BY CANCER TYPE, 2020–2028 ($MILLION)
TABLE 50.FRANCE LIQUID BIOPSY MARKET, BY END USER, 2020–2028 ($MILLION)
TABLE 51.UK LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2020–2028 ($MILLION)
TABLE 52.UK LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2020–2028 ($MILLION)
TABLE 53.UK LIQUID BIOPSY MARKET, BY CANCER TYPE, 2020–2028 ($MILLION)
TABLE 54.UK LIQUID BIOPSY MARKET, BY END USER, 2020–2028 ($MILLION)
TABLE 55.ITALY LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2020–2028 ($MILLION)
TABLE 56.ITALY LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2020–2028 ($MILLION)
TABLE 57.ITALY LIQUID BIOPSY MARKET, BY CANCER TYPE, 2020–2028 ($MILLION)
TABLE 58.ITALY LIQUID BIOPSY MARKET, BY END USER, 2020–2028 ($MILLION)
TABLE 59.SPAIN LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2020–2028 ($MILLION)
TABLE 60.SPAIN LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2020–2028 ($MILLION)
TABLE 61.SPAIN LIQUID BIOPSY MARKET, BY CANCER TYPE, 2020–2028 ($MILLION)
TABLE 62.SPAIN LIQUID BIOPSY MARKET, BY END USER, 2020–2028 ($MILLION)
TABLE 63.REST OF EUROPE LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2020–2028 ($MILLION)
TABLE 64.REST OF EUROPE LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2020–2028 ($MILLION)
TABLE 65.REST OF EUROPE LIQUID BIOPSY MARKET, BY CANCER TYPE, 2020–2028 ($MILLION)
TABLE 66.REST OF EUROPE LIQUID BIOPSY MARKET, BY END USER, 2020–2028 ($MILLION)
TABLE 67.ASIA-PACIFIC LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2020–2028 ($MILLION)
TABLE 68.ASIA-PACIFIC LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2020–2028 ($MILLION)
TABLE 69.ASIA-PACIFIC LIQUID BIOPSY MARKET, BY CANCER TYPE, 2020–2028 ($MILLION)
TABLE 70.ASIA-PACIFIC LIQUID BIOPSY MARKET, BY END USER, 2020–2028 ($MILLION)
TABLE 71.ASIA-PACIFIC LIQUID BIOPSY MARKET, BY COUNTRY, 2020–2028 ($MILLION)
TABLE 72.JAPAN LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2020–2028 ($MILLION)
TABLE 73.JAPAN LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2020–2028 ($MILLION)
TABLE 74.JAPAN LIQUID BIOPSY MARKET, BY CANCER TYPE, 2020–2028 ($MILLION)
TABLE 75.JAPAN LIQUID BIOPSY MARKET, BY END USER, 2020–2028 ($MILLION)
TABLE 76.CHINA LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2020–2028 ($MILLION)
TABLE 77.CHINA LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2020–2028 ($MILLION)
TABLE 78.CHINA LIQUID BIOPSY MARKET, BY CANCER TYPE, 2020–2028 ($MILLION)
TABLE 79.CHINA LIQUID BIOPSY MARKET, BY END USER, 2020–2028 ($MILLION)
TABLE 80.AUSTRALIA LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2020–2028 ($MILLION)
TABLE 81.AUSTRALIA LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2020–2028 ($MILLION)
TABLE 82.AUSTRALIA LIQUID BIOPSY MARKET, BY CANCER TYPE, 2020–2028 ($MILLION)
TABLE 83.AUSTRALIA LIQUID BIOPSY MARKET, BY END USER, 2020–2028 ($MILLION)
TABLE 84.INDIA LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2020–2028 ($MILLION)
TABLE 85.INDIA LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2020–2028 ($MILLION)
TABLE 86.INDIA LIQUID BIOPSY MARKET, BY CANCER TYPE, 2020–2028 ($MILLION)
TABLE 87.INDIA LIQUID BIOPSY MARKET, BY END USER, 2020–2028 ($MILLION)
TABLE 88.SOUTH KOREA LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2020–2028 ($MILLION)
TABLE 89.SOUTH KOREA LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2020–2028 ($MILLION)
TABLE 90.SOUTH KOREA LIQUID BIOPSY MARKET, BY CANCER TYPE, 2020–2028 ($MILLION)
TABLE 91.SOUTH KOREA LIQUID BIOPSY MARKET, BY END USER, 2020–2028 ($MILLION)
TABLE 92.TAIWAN LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2020–2028 ($MILLION)
TABLE 93.TAIWAN LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2020–2028 ($MILLION)
TABLE 94.TAIWAN LIQUID BIOPSY MARKET, BY CANCER TYPE, 2020–2028 ($MILLION)
TABLE 95.TAIWAN LIQUID BIOPSY MARKET, BY END USER, 2020–2028 ($MILLION)
TABLE 96.REST OF ASIA-PACIFIC LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2020–2028 ($MILLION)
TABLE 97.REST OF ASIA-PACIFIC LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2020–2028 ($MILLION)
TABLE 98.REST OF ASIA-PACIFIC LIQUID BIOPSY MARKET, BY CANCER TYPE, 2020–2028 ($MILLION)
TABLE 99.REST OF ASIA-PACIFIC LIQUID BIOPSY MARKET, BY END USER, 2020–2028 ($MILLION)
TABLE 100.LAMEA LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2020–2028 ($MILLION)
TABLE 101.LAMEA LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2020–2028 ($MILLION)
TABLE 102.LAMEA LIQUID BIOPSY MARKET, BY CANCER TYPE, 2020–2028 ($MILLION)
TABLE 103.LAMEA LIQUID BIOPSY MARKET, BY END USER, 2020–2028 ($MILLION)
TABLE 104.LAMEA LIQUID BIOPSY MARKET, BY COUNTRY, 2020–2028 ($MILLION)
TABLE 105.BRAZIL LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2020–2028 ($MILLION)
TABLE 106.BRAZIL LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2020–2028 ($MILLION)
TABLE 107.BRAZIL LIQUID BIOPSY MARKET, BY CANCER TYPE, 2020–2028 ($MILLION)
TABLE 108.BRAZIL LIQUID BIOPSY MARKET, BY END USER, 2020–2028 ($MILLION)
TABLE 109.TURKEY LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2020–2028 ($MILLION)
TABLE 110.TURKEY LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2020–2028 ($MILLION)
TABLE 111.TURKEY LIQUID BIOPSY MARKET, BY CANCER TYPE, 2020–2028 ($MILLION)
TABLE 112.TURKEY LIQUID BIOPSY MARKET, BY END USER, 2020–2028 ($MILLION)
TABLE 113.SAUDI ARABIA LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2020–2028 ($MILLION)
TABLE 114.SAUDI ARABIA LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2020–2028 ($MILLION)
TABLE 115.SAUDI ARABIA LIQUID BIOPSY MARKET, BY CANCER TYPE, 2020–2028 ($MILLION)
TABLE 116.SAUDI ARABIA LIQUID BIOPSY MARKET, BY END USER, 2020–2028($MILLION)
TABLE 117.SOUTH AFRICA LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2020–2028 ($MILLION)
TABLE 118.SOUTH AFRICA LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2020–2028 ($MILLION)
TABLE 119.SOUTH AFRICA LIQUID BIOPSY MARKET, BY CANCER TYPE, 2020–2028 ($MILLION)
TABLE 120.SOUTH AFRICA LIQUID BIOPSY MARKET, BY END USER, 2020–2028 ($MILLION)
TABLE 121.REST OF LAMEA LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2020–2028 ($MILLION)
TABLE 122.REST OF LAMEA LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2020–2028 ($MILLION)
TABLE 123.REST OF LAMEA LIQUID BIOPSY MARKET, BY CANCER TYPE, 2020–2028 ($MILLION)
TABLE 124.REST OF LAMEA LIQUID BIOPSY MARKET, BY END USER, 2020–2028 ($MILLION)
TABLE 125.BIO-RAD: COMPANY SNAPSHOT
TABLE 126.MYRIAD: OERATING SEGMENT
TABLE 127.BIO-RAD: PRODUCT PORTFOLIO
TABLE 128.BIO-RAD: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 129.BIOCEPT: COMPANY SNAPSHOT
TABLE 130.BIOCEPT: PRODUCT PORTFOLIO
TABLE 131.BIOCEPT: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 132.GUARDANT: COMPANY SNAPSHOT
TABLE 133.GUARDANT: OPERATING SEGMENTS
TABLE 134.GUARDANT: PRODUCT PORTFOLIO
TABLE 135.BIOCEPT: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 136.ILLUMINA: COMPANY SNAPSHOT
TABLE 137.ILLUMINA: OPERATING SEGMENTS
TABLE 138.ILLUMINA: PRODUCT PORTFOLIO
TABLE 139.ROCHE: COMPANY SNAPSHOT
TABLE 140.ROCHE: OPERATING SEGMENTS
TABLE 141.ROCHE: PRODUCT PORTFOLIO
TABLE 142.ROCHE: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 143.J&J: COMPANY SNAPSHOT
TABLE 144.J&J: OPERATING BUSINESS SEGMENTS
TABLE 145.J&J: PRODUCT PORTFOLIO
TABLE 146.LABCORP: COMPANY SNAPSHOT
TABLE 147.LABCORP: OPERATING SEGMENTS
TABLE 148.LABCORP: PRODUCT PORTFOLIO
TABLE 149.ROCHE: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 150.MDXHEALTH: COMPANY SNAPSHOT
TABLE 151.MDXHEALTH: PRODUCT PORTFOLIO
TABLE 152.ROCHE: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 153.QIAGEN: COMPANY SNAPSHOT
TABLE 154.QIAGEN: PRODUCT PORTFOLIO
TABLE 155.QIAGEN: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 156.THERMO: COMPANY SNAPSHOT
TABLE 157.THERMO: OPERATING SEGMENTS
TABLE 158.THERMO: PRODUCT PORTFOLIO
TABLE 159.THERMO: KEY STRATEGIC MOVES AND DEVELOPMENTS

LIST OF FIGURES

FIGURE 01.GLOBAL LIQUID BIOPSYMARKET SEGMENTATION
FIGURE 02.TOP INVESTMENT POCKETS
FIGURE 03.TOP WINNING STRATEGIES, BY YEAR, 2018–2021
FIGURE 04.TOP WINNING STRATEGIES, BY DEVELOPMENT, 2018–2021
FIGURE 05.TOP WINNING STRATEGIES, BY COMPANY, 2018–2021
FIGURE 06.MODERATE BARGAINING POWER OF BUYERS
FIGURE 07.MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 08.MODERATE THREAT OF NEW ENTRANTS
FIGURE 10.MODERATE COMPETITIVE RIVALRY
FIGURE 11.TOP PLAYER POSITIONING, 2020
FIGURE 12.PIE CHART FOR CANCER CASES DIAGNOSED IN 2020
FIGURE 13.COMPARATIVE SHARE ANALYSIS OF LIQUID BIOPSY MARKET FOR KITS & REAGENTS, BY COUNTRY, 2020 & 2028 (%)
FIGURE 14.COMPARATIVE SHARE ANALYSIS OF LIQUID BIOPSY MARKET FOR PLATFORMS & INSTRUMENTS, BY COUNTRY, 2020 & 2028 (%)
FIGURE 15.COMPARATIVE SHARE ANALYSIS OF LIQUID BIOPSY MARKET FOR SERVICES, BY COUNTRY, 2020 & 2028 (%)
FIGURE 16.COMPARATIVE ANALYSIS OF LIQUID BIOPSY MARKET FOR CIRCULATING TUMOR CELL, BY COUNTRY, 2020 & 2028 (%)
FIGURE 17.COMPARATIVE ANALYSIS OF LIQUID BIOPSY MARKET FOR CIRCULATING TUMOR DNA, BY COUNTRY, 2020 & 2028 (%)
FIGURE 18.COMPARATIVE ANALYSIS OF LIQUID BIOPSY MARKET FOR EXTRACELLULAR VESICLES, BY COUNTRY, 2020 & 2028 (%)
FIGURE 19.COMPARATIVE ANALYSIS OF LIQUID BIOPSY MARKET FOR OTHER BIOMARKERS, BY COUNTRY, 2020 & 2028 (%)
FIGURE 20.COMPARATIVE ANALYSIS OF LIQUID BIOPSY MARKET FOR LUNG CANCER, BY COUNTRY, 2020 & 2028 (%)
FIGURE 21.COMPARATIVE ANALYSIS OF LIQUID BIOPSY MARKET FOR BREAST CANCER, BY COUNTRY, 2020 & 2028 (%)
FIGURE 22.COMPARATIVE ANALYSIS OF LIQUID BIOPSY MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2020 & 2028 (%)
FIGURE 23.COMPARATIVE ANALYSIS OF LIQUID BIOPSY MARKET FOR PROSTATE CANCER, BY COUNTRY, 2020 & 2028 (%)
FIGURE 24.COMPARATIVE ANALYSIS OF LIQUID BIOPSY MARKET FOR LIVER CANCER, BY COUNTRY, 2020 & 2028 (%)
FIGURE 25.COMPARATIVE ANALYSIS OF LIQUID BIOPSY MARKET FOR OTHER CANCER, BY COUNTRY, 2020 & 2028 (%)
FIGURE 26.COMPARATIVE ANALYSIS OF LIQUID BIOPSY MARKET FOR HOSPITAL AND LABORATORY, BY COUNTRY, 2020 & 2028 (%)
FIGURE 27.COMPARATIVE ANALYSIS OF LIQUID BIOPSY MARKET FOR GOVERNMENT AND ACADEMIC RESEARCH CENTER, BY COUNTRY, 2020 & 2028 (%)
FIGURE 28.BIO-RAD: NET SALES, 2018–2020 ($MILLION)
FIGURE 29.BIO-RAD: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 30.BIO-RAD: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 31.BIOCEPT: NET SALES, 2018–2020 ($MILLION)
FIGURE 32.GUARDANT: NET SALES, 2018–2020 ($MILLION)
FIGURE 33.GUARDANT: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 34.GUARDANT: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 35.ILLUMINA: NET SALES, 2018–2020 ($MILLION)
FIGURE 36.ILLUMINA: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 37.ILLUMINA: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 38.ROCHE: NET SALES, 2018–2020 ($MILLION)
FIGURE 39.ROCHE: REVENUE SHARE, BY SEGMENT, 2020 ($MILLION)
FIGURE 40.J&J: NET SALES, 2018–2020 ($MILLION)
FIGURE 41.J&J: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 42.J&J: REVENUE SHARE BY REGION, 2020(%)
FIGURE 43.LABCORP: REVENUE, 2018–2020 ($MILLION)
FIGURE 44.LABCORP: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 45.LABCORP: REVENUE SHARE, BY REGION, 2020 (%)
FIGURE 46.MDXHEALTH: NET SALES, 2018–2020 ($MILLION)
FIGURE 47.MDXHEALTH: REVENUE SHARE BY REGION, 2020(%)
FIGURE 48.QIAGEN: NET SALES, 2018–2020 ($MILLION)
FIGURE 49.QIAGEN: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 50.THERMO: NET SALES, 2018–2020 ($MILLION)
FIGURE 51.THERMO: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 52.THERMO: REVENUE SHARE, BY REGION, 2020 (%)

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[液体生検の世界市場2021年-2028年:製品・サービス別(キット・試薬、プラットフォーム・機器、サービス)、循環バイオマーカー別、がん種類別、エンドユーザー別]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆